Medical management of stable angina

Hellenic Journal of Cardiology

Volumn 55, Issue 4, 2014, Pages 272-280

  Andrikopoulos, George ^a   Parissis, John ^b   Filippatos, Gerasimos ^b   Nikolaou, Maria ^c   Pantos, Konstantinos ^d   Voudris, Vasileios ^e   Karvounis, Haralambos ^f   Alexopoulos, Dimitris ^g   Goudevenos, John ^h  

^a HENRY DUNANT HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Hellenic Cardiovascular Research Society   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e ONASSIS CARDIAC SURGERY CENTER   (Greece)

^f AHEPA UNIVERSITY HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^h UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Hellenic cardiovascular research society; Medical management; Stable angina; Statement

Indexed keywords

AMLODIPINE; ATENOLOL; BISOPROLOL; CARVEDILOL; DILTIAZEM; FELODIPINE; IVABRADINE; METOPROLOL; NIFEDIPINE; NITRIC ACID DERIVATIVE; RANOLAZINE; VERAPAMIL; VASODILATOR AGENT;

ALGORITHM; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); PREVALENCE; PROGNOSIS; QUALITY OF LIFE; SINUS RHYTHM; STABLE ANGINA PECTORIS; ANGINA, STABLE; PRACTICE GUIDELINE;

ALGORITHMS; ANGINA, STABLE; HUMANS; PRACTICE GUIDELINES AS TOPIC; VASODILATOR AGENTS;

EID: 84904641810     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27: 1341-1381.
2. Fihn SD, Gardin JM, Abrams J, Berra K, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60: e44-e164. doi: 10.1016/j.jacc.2012.07.013. Epub 2012 Nov 19.
3. National Clinical Guidelines Centre. Stable angina. The management of stable angina. http://guidance.nice.org.uk/CG/Wave17/25. [Accessed May 27, 2012].
4. Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med. 2008; 168: 1310-1316.
5. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006; 27: 1610-1619.
6. Margolis JR, Gillum RF, Feinleib M, Brasch R, Fabsitz R. Community surveillance for coronary heart disease: the Fra- mingham Cardiovascular Disease survey. Comparisons with the Framingham Heart Study and previous short-term studies. Am J Cardiol. 1976; 37: 61-67.
7. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972; 29: 154-163.
8. Reunanen A, Suhonen O, Aromaa A, Knekt P, Pyörälä K. Incidence of different manifestations of coronary heart disease in middle-aged Finnish men and women. Acta Med Scand. 1985; 218: 19-26.
9. Ducimetière P, Ruidavets JB, Montaye M, Haas B, Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol. 2001; 30: 1057-1062.
10. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999; 353: 1547-1557.
11. Maniadakis N, Kourlaba G, Fragoulakis V. Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; a telephone survey. BMC Cardiovasc Disord. 2011; 11: 16.
12. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635-1701.
13. Andrikopoulos G, Pastromas S, Kartalis A, et al. Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study. Hellenic J Cardiol. 2012; 53: 118-126.
14. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988; 260: 2088-2093.
15. Freemantle N, Urdahl H, Eastaugh J, Hobbs FD. What is the place of beta-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. Prog Cardiovasc Dis. 2002; 44: 243-250.
16. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004; 364: 1684-1689.
17. Bangalore S, Steg G, Deedwania P, et al. B-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012; 308: 1340-1349.
18. Andrikopoulos G, Richter D, Sakellariou D, et al. High prevalence and diminished awareness of overweight and obesity in a mediterranean population. An alarming call for action. Open Cardiovasc Med J. 2012; 6: 141-146.
19. Andrikopoulos G, Pipilis A, Goudevenos J, et al; HELIOS Study Investigators. Epidemiological characteristics, management and early outcome of acute myocardial infarction in Greece: the HELlenic Infarction Observation Study. Hellenic J Cardiol. 2007; 48: 325-334.
20. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000; 342: 905-912.
21. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92: 1326-1331.
22. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of longacting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004; 364: 849-857.
23. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362: 1527-1535.
24. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003; 289: 2534-2544.
25. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003; 21: 1055-1076.
26. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994; 8: 611-623.
27. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345: 669-685.
28. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994; 343: 1115-1122.
29. Andrikopoulos G, Tzeis S, Mantas I, et al. Epidemiological characteristics and in-hospital management of acute coronary syndrome patients in Greece: results from the TARGET study. Hellenic J Cardiol. 2012; 53: 33-40.
30. Andrikopoulos G, Dasopoulou C, Sakellariou D, et al. Ivabradine: a selective If current inhibitor in the treatment of stable angina. Recent Pat Cardiovasc Drug Discov. 2006; 1: 277-282.
31. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009; 30: 540-548.
32. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005; 26: 2529-2536.
33. Heusch G, Baumgart D, Camici P, et al. α-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2001; 101: 689-694.
34. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 807-816.
35. Swedberg K, Komajda M, Böhm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376: 875-885.
36. Soliman D, Wang L, Hamming KS, et al. Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemiaand cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange. J Pharmacol Exp Ther. 2012; 343: 325-332.
37. Tzeis S, Andrikopoulos G. Antiarrhythmic properties of ranolazine-from bench to bedside. Expert Opin Investig Drugs. 2012; 21: 1733-1741.
38. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005; 95: 311-316.
39. Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009; 2: 1301-1309.
40. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43: 1375-1382.
41. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309-316.
42. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006; 48: 566-575.
43. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007; 297: 1775-1783.
44. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009; 53: 15101516.
45. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009; 119: 2032-2039.
46. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non STsegment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116: 1647-1652.
47. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011; 34: 1600-1606.
48. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011; 108: 673-676.
49. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012; 35: 302-307.
50. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012; 110: 673-677.